Opportunities and challenges in the design of implantable biodegradable polymeric systems for the delivery of antimicrobial agents and vaccines

Abstract An increasing number of implantable biodegradable polymeric drug systems are now in clinical use or undergoing experimental and clinical investigations for diverse therapeutic applications. This article summarizes the use of copolymers of lactic and glycolic acid as carrier materials for the controlled release of antigens for vaccination and of chemotherapeutic agents for the therapy of chronic microbial diseases. These approaches illustrate some of the important conceptual and technical issues that must be considered in the future development of implantable biodegradable polymeric systems. These systems offer considerable promise for achieving controlled release of the new classes of biological mediators produced by recombinant technology, particularly those vaccines intended for use in the Third World. The future development of these systems will almost certainly require the use of specialized approaches to particular delivery problems but, overall, the development is viewed with considerable optimism.

[1]  J M Brady,et al.  Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios. , 1977, Journal of biomedical materials research.

[2]  Levis Wr.  Treatment of leprosy in the United States. , 1984, Bulletin of the New York Academy of Medicine.

[3]  H. Huikeshoven.  Patient compliance in leprosy control: a necessity in old and new regimens. , 1985, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[4]  R. F. Johnston,et al.  [Chemotherapy of pulmonary tuberculosis]. , 1969, Zhonghua jie he he hu xi xi ji bing za zhi = Chinese journal of tuberculosis and respiratory diseases.

[5]  I. D. Bobrowitz,et al.  Ethambutol-isoniazid versus PAS-isoniazid in original treatment of pulmonary tuberculosis. , 1967, The American review of respiratory disease.

[6]  D. Wise,et al.  Sustained release of a dual antimalarial system , 1979, The Journal of pharmacy and pharmacology.

[7]  R. Rees,et al.  Transmission of human leprosy to the mouse and its clinical implications. , 1970, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[8]  A. Rouillon,et al.  ACONCURRENT COMPARISON OF INTERMITTENT (TWICE-WEEKLY) ISONIAZID PLUS STREPTOMYCIN AND DAILY ISONIAZID PLUS PAS IN THE DOMICILIARY TREATMENT OF PULMONARY TUBERCULOSIS; TUBERCULOSIS CHEMOTHERAPY CENTRE, MADRAS. , 1964, Bulletin of the World Health Organization.

[9]  J. Fleetham,et al.  Resin hemoperfusion as treatment for theophylline-induced seizures. , 1979, Chest.

[10]  D. Wise,et al.  An injectable sustained release fertility control system. , 1976, Contraception.

[11]  W. Addington,et al.  Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. , 1979, Chest.

[12]  R. Langer.  [4] Polymers for the sustained release of macromolecules: Their use in a single-step method of immunization , 1981 .

[13]  O. Weiser,et al.  Ambulatory treatment of tuberculosis. Results in 105 tuberculous patients treated with chemotherapy and active physical rehabilitation. , 1961, The American review of respiratory disease.

[14]  P. Hopewell,et al.  Operational evaluation of treatment for tuberculosis. Results of a "standard" 12-month regimen in Peru. , 1984, The American review of respiratory disease.

[15]  D. Wise,et al.  Evaluation of wound-covering materials. , 1977, Journal of biomedical materials research.

[16]  D. Mitchison,et al.  SHORT-COURSE CHEMOTHERAPY FOR TUBERCULOSIS , 1976, The Lancet.

[17]  M. Siddique,et al.  Irregularity of treatment in leprosy patients: its magnitude and causes. , 1979, Leprosy in India.

[18]  D. Wise,et al.  Sustained release of an antimalarial drug using a copolymer of glycolic/lactic acid. , 1976, Life sciences.

[19]  Collier Pj.  A study of case-holding in leprosy patients in Asia, based on duration of treatment, 1976-80. , 1983 .

[20]  E. Gaensler.  The surgery for pulmonary tuberculosis. , 2015, The American review of respiratory disease.

[21]  O. K. Skinsnes.  LEPROSY IN SOCIETY. II. THE PATTERN OF CONCEPT AND REACTION TO LEPROSY IN ORIENTAL ANTIQUITY. , 1964, Leprosy review.

[22]  W. Fox,et al.  A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. , 1966, Bulletin of the World Health Organization.

[23]  D. Wise,et al.  Development of polylactic/glycolic acid delivery systems for use in treatment of narcotic addiction. , 1976, National Institute on Drug Abuse research monograph series.

[24]  W. Fox,et al.  A 5-year study of patients with pulmonary tuberculosis in a concurrent comparison of home and sanatorium treatment for one year with isoniazid plus PAS. , 1966, Bulletin of the World Health Organization.

[25]  L. M. Bechelli,et al.  The leprosy problem in the world. , 1966, Bulletin of the World Health Organization.

[26]  D. Wise,et al.  POLYLACTIC ACID AS A BIODEGRADABLE CARRIER FOR CONTRACEPTIVE STEROIDS , 1973 .

[27]  W. Feldman,et al.  Streptomycin in Treatment of Clinical Tuberculosis: a Preliminary Report. , 1945 .

[28]  C. Shepard.  THE EXPERIMENTAL DISEASE THAT FOLLOWS THE INJECTION OF HUMAN LEPROSY BACILLI INTO FOOT-PADS OF MICE , 1960, The Journal of experimental medicine.

[29]  P. Chapman.  Ingrowing Toe-nail , 1934 .

[30]  D. Wise,et al.  Lactic/glycolic acid polymers as narcotic antagonist delivery systems. , 1975, Life sciences.

[31]  W. Fox,et al.  The role of diet in the treatment of pulmonary tuberculosis. An evaluation in a controlled chemotherapy study in home and sanatorium patients in South India. , 1961, Bulletin of the World Health Organization.

[32]  W. Mcdermott,et al.  Streptomycin in the treatment of tuberculosis in humans, meningitis and generalized hematogenous tuberculosis. , 1947, Annals of internal medicine.

[33]  D. Wise,et al.  Sustained release of sulphadiazine , 1978, The Journal of pharmacy and pharmacology.

[34]  Hertroijs Ar.  A study of some factors affecting the attendance of patients in a leprosy control scheme. , 1974 .

[35]  A. Miller,et al.  The therapy of pulmonary tuberculosis in Kenya: a comparison of the results achieved in controlled clinical trials with those achieved by the routine treatment services. , 1970, Tubercle.

[36]  C. Shepard.  Chemotherapy of Leprosy , 1982, The Lancet.